Actuate Therapeutics (ACTU) Competitors $9.54 +0.34 (+3.70%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. CRON, XERS, DNTH, ZYBT, ANAB, KALV, ABUS, TRVI, CDXC, and PHARShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Cronos Group (CRON), Xeris Biopharma (XERS), Dianthus Therapeutics (DNTH), Zhengye Biotechnology (ZYBT), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), Trevi Therapeutics (TRVI), ChromaDex (CDXC), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Cronos Group Xeris Biopharma Dianthus Therapeutics Zhengye Biotechnology AnaptysBio KalVista Pharmaceuticals Arbutus Biopharma Trevi Therapeutics ChromaDex Pharming Group Actuate Therapeutics (NASDAQ:ACTU) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Is ACTU or CRON more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Actuate Therapeutics' return on equity of 0.00% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Cronos Group -42.65%-2.56%-2.47% Does the media prefer ACTU or CRON? In the previous week, Actuate Therapeutics had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Actuate Therapeutics and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.52 beat Actuate Therapeutics' score of 0.49 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, ACTU or CRON? Actuate Therapeutics has higher earnings, but lower revenue than Cronos Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/ACronos Group$117.62M6.13-$73.96M$0.1018.70 Do insiders & institutionals have more ownership in ACTU or CRON? 8.7% of Cronos Group shares are held by institutional investors. 69.3% of Actuate Therapeutics shares are held by company insiders. Comparatively, 6.9% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in ACTU or CRON? Cronos Group received 462 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 61.13% of users gave Cronos Group an outperform vote. CompanyUnderperformOutperformActuate TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesCronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Do analysts rate ACTU or CRON? Actuate Therapeutics currently has a consensus target price of $20.50, suggesting a potential upside of 115.79%. Cronos Group has a consensus target price of $3.50, suggesting a potential upside of 87.17%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Actuate Therapeutics is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryActuate Therapeutics beats Cronos Group on 10 of the 14 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.55M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / SalesN/A241.49397.62103.35Price / CashN/A65.8538.1834.62Price / BookN/A6.486.734.25Net Income-$24.75M$143.41M$3.22B$248.18M7 Day Performance5.09%2.30%1.58%1.25%1 Month Performance41.79%7.14%4.05%3.76%1 Year PerformanceN/A-2.61%15.75%5.28% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$9.50+3.3%$20.50+115.8%N/A$185.55MN/A0.0010CRONCronos Group1.5289 of 5 stars$1.83+1.7%$3.50+91.3%-36.1%$705.30M$117.62M-14.08450Upcoming EarningsXERSXeris Biopharma3.5759 of 5 stars$4.41+2.3%$6.10+38.3%+161.1%$689.66M$203.07M-9.80290Upcoming EarningsNews CoverageHigh Trading VolumeDNTHDianthus Therapeutics1.7349 of 5 stars$21.45-1.0%$54.33+153.3%+2.3%$689.10M$6.24M-8.5880Upcoming EarningsNews CoveragePositive NewsZYBTZhengye BiotechnologyN/A$14.15+35.5%N/AN/A$667.40M$189.75M0.00278ANABAnaptysBio2.5205 of 5 stars$21.33+3.0%$33.63+57.6%-8.7%$654.13M$91.28M-3.51100Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsKALVKalVista Pharmaceuticals4.3785 of 5 stars$13.00+0.1%$24.83+91.0%+21.3%$646.31MN/A-3.57100Positive NewsABUSArbutus Biopharma2.0074 of 5 stars$3.34+1.5%$5.50+64.7%+30.0%$639.54M$6.17M-7.7790TRVITrevi Therapeutics3.5998 of 5 stars$6.59+1.9%$17.56+166.5%+135.8%$637.13MN/A-14.9820Upcoming EarningsNews CoveragePositive NewsCDXCChromaDex2.3331 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastPHARPharming Group2.5184 of 5 stars$8.75+2.8%$30.00+242.9%-6.6%$595.27M$297.20M-33.65280Upcoming EarningsShort Interest ↓News CoveragePositive News Related Companies and Tools Related Companies CRON Competitors XERS Competitors DNTH Competitors ZYBT Competitors ANAB Competitors KALV Competitors ABUS Competitors TRVI Competitors CDXC Competitors PHAR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACTU Stock Free ACTU Stock Alerts